Rictor_1 shRNA Citations (30)
Originally described in: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.Sarbassov DD, Guertin DA, Ali SM, Sabatini DM Science 2005 Feb 18;307(5712):1098-101. PubMed Journal
Articles Citing Rictor_1 shRNA
| Articles |
|---|
| Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Proc Natl Acad Sci U S A. 2006 Sep 19. 103(38):14182-7. PubMed |
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
Wang L, Harris TE, Roth RA, Lawrence JC.
J Biol Chem. 2007 Jul 6. 282(27):20036-44.
PubMed
Associated Plasmids |
| TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Copp J, Manning G, Hunter T. Cancer Res. 2009 Mar 1. 69(5):1821-7. PubMed |
| The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. Clippinger AJ, Maguire TG, Alwine JC. J Virol. 2011 Apr;85(8):3930-9. doi: 10.1128/JVI.01913-10. Epub 2011 Feb 9. PubMed |
| LAMTOR1 depletion induces p53-dependent apoptosis via aberrant lysosomal activation. Malek M, Guillaumot P, Huber AL, Lebeau J, Petrilli V, Kfoury A, Mikaelian I, Renno T, Manie SN. Cell Death Dis. 2012 Apr 19;3:e300. doi: 10.1038/cddis.2012.39. PubMed |
| mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state. Cang C, Zhou Y, Navarro B, Seo YJ, Aranda K, Shi L, Battaglia-Hsu S, Nissim I, Clapham DE, Ren D. Cell. 2013 Feb 14;152(4):778-90. doi: 10.1016/j.cell.2013.01.023. Epub 2013 Feb 7. PubMed |
| Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Wang C, Yi T, Qin L, Maldonado RA, von Andrian UH, Kulkarni S, Tellides G, Pober JS. J Clin Invest. 2013 Apr;123(4):1677-93. doi: 10.1172/JCI66204. Epub 2013 Mar 8. PubMed |
| Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-beta-independent mechanism. Mikaelian I, Malek M, Gadet R, Viallet J, Garcia A, Girard-Gagnepain A, Hesling C, Gillet G, Gonzalo P, Rimokh R, Billaud M. Cancer Res. 2013 Nov 15;73(22):6621-31. doi: 10.1158/0008-5472.CAN-13-0560. Epub 2013 Sep 27. PubMed |
| Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Tandon M, Chen Z, Pratap J. Breast Cancer Res. 2014 Jan 30;16(1):R16. doi: 10.1186/bcr3611. PubMed |
| Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. Wang C, Qin L, Manes TD, Kirkiles-Smith NC, Tellides G, Pober JS. J Exp Med. 2014 Mar 10;211(3):395-404. doi: 10.1084/jem.20131125. Epub 2014 Feb 10. PubMed |
| Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3beta signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Kim EY, Kim A, Kim SK, Kim HJ, Chang J, Ahn CM, Chang YS. Respir Res. 2014 Feb 26;15:26. doi: 10.1186/1465-9921-15-26. PubMed |
| Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Selvaraj N, Budka JA, Ferris MW, Jerde TJ, Hollenhorst PC. Mol Cancer. 2014 Mar 19;13:61. doi: 10.1186/1476-4598-13-61. PubMed |
| A critical role for the mTORC2 pathway in lung fibrosis. Chang W, Wei K, Ho L, Berry GJ, Jacobs SS, Chang CH, Rosen GD. PLoS One. 2014 Aug 27;9(8):e106155. doi: 10.1371/journal.pone.0106155. eCollection 2014. PubMed |
| mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY. PLoS One. 2014 Sep 2;9(9):e104413. doi: 10.1371/journal.pone.0104413. eCollection 2014. PubMed |
Lanthionine synthetase C-like protein 2 (LanCL2) is a novel regulator of Akt.
Zeng M, van der Donk WA, Chen J.
Mol Biol Cell. 2014 Dec 1;25(24):3954-61. doi: 10.1091/mbc.E14-01-0004. Epub 2014 Oct 1.
PubMed
Associated Plasmids |
Identification of an oncogenic RAB protein.
Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL.
Science. 2015 Oct 9;350(6257):211-7. doi: 10.1126/science.aaa4903. Epub 2015 Sep 3.
PubMed
Associated Plasmids |
| Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers. Morrison-Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Cancer Res. 2016 Apr 25. pii: canres.3393.2015. PubMed |
| Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. Cao J, Tyburczy ME, Moss J, Darling TN, Widlund HR, Kwiatkowski DJ. J Clin Invest. 2017 Jan 3;127(1):349-364. doi: 10.1172/JCI84262. Epub 2016 Dec 5. PubMed |
| Pegylated IFN-alpha suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. Liu WL, Yang HC, Hsu CS, Wang CC, Wang TS, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14799-14804. doi: 10.1073/pnas.1618517114. Epub 2016 Dec 6. PubMed |
| Defects in autophagosome-lysosome fusion underlie Vici syndrome, a neurodevelopmental disorder with multisystem involvement. Hori I, Otomo T, Nakashima M, Miya F, Negishi Y, Shiraishi H, Nonoda Y, Magara S, Tohyama J, Okamoto N, Kumagai T, Shimoda K, Yukitake Y, Kajikawa D, Morio T, Hattori A, Nakagawa M, Ando N, Nishino I, Kato M, Tsunoda T, Saitsu H, Kanemura Y, Yamasaki M, Kosaki K, Matsumoto N, Yoshimori T, Saitoh S. Sci Rep. 2017 Jun 14;7(1):3552. doi: 10.1038/s41598-017-02840-8. PubMed |
| mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS. Mol Cell. 2017 Jul 6;67(1):128-138.e7. doi: 10.1016/j.molcel.2017.05.030. Epub 2017 Jun 22. PubMed |
| mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation. Maiti S, Mondal S, Satyavarapu EM, Mandal C. Cell Death Dis. 2017 Jul 13;8(7):e2926. doi: 10.1038/cddis.2017.296. PubMed |
| mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Chiang CT, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM. Cancer Lett. 2018 Oct 10;434:152-159. doi: 10.1016/j.canlet.2018.07.025. Epub 2018 Jul 21. PubMed |
| MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress. Ozturk DG, Kocak M, Akcay A, Kinoglu K, Kara E, Buyuk Y, Kazan H, Gozuacik D. Autophagy. 2019 Mar;15(3):375-390. doi: 10.1080/15548627.2018.1531197. Epub 2018 Oct 16. PubMed |
| An Excitable Ras/PI3K/ERK Signaling Network Controls Migration and Oncogenic Transformation in Epithelial Cells. Zhan H, Bhattacharya S, Cai H, Iglesias PA, Huang CH, Devreotes PN. Dev Cell. 2020 Sep 14;54(5):608-623.e5. doi: 10.1016/j.devcel.2020.08.001. Epub 2020 Sep 1. PubMed |
| A compendium of kinetic modulatory profiles identifies ferroptosis regulators. Conlon M, Poltorack CD, Forcina GC, Armenta DA, Mallais M, Perez MA, Wells A, Kahanu A, Magtanong L, Watts JL, Pratt DA, Dixon SJ. Nat Chem Biol. 2021 Jun;17(6):665-674. doi: 10.1038/s41589-021-00751-4. Epub 2021 Mar 8. PubMed |
| Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Kong BS, Min SH, Lee C, Cho YM. Cell Rep. 2021 Jul 27;36(4):109447. doi: 10.1016/j.celrep.2021.109447. PubMed |
| Epithelial-mesenchymal reprogramming by KLF4-regulated Rictor expression contributes to metastasis of non-small cell lung cancer cells. Zhou H, Guan Q, Hou X, Liu L, Zhou L, Li W, Liu H. Int J Biol Sci. 2022 Jul 18;18(13):4869-4883. doi: 10.7150/ijbs.73548. eCollection 2022. PubMed |
| MTORC2 is a physiological hydrophobic motif kinase of S6 Kinase 1. Majeed ST, Majeed R, Malik AA, Andrabi KI. Biochim Biophys Acta Mol Cell Res. 2023 Apr;1870(4):119449. doi: 10.1016/j.bbamcr.2023.119449. Epub 2023 Feb 28. PubMed |
| mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance. Bu C, Zhao L, Wang L, Yu Z, Zhou J. Oncol Res. 2023 Jun 27;31(4):495-503. doi: 10.32604/or.2023.029309. eCollection 2023. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.